LPS cells are induced to differentiate in vitro on PPARγ agonist exposure.64 Although repurposing PPARγ agonists used to treat diabetes produced disappointing phase II results in LPS,65,66 more recent phase I results with efatutazone, a third-generation thiazolidinedione PPARγ agonist, were more encouraging, with partial response sustained at 23 months in one patient with MLPS.67 A single-arm phase II trial of efatutazone in advanced MLPS is ongoing (NCT02249949). This evidence concerns the gene PPARG and diabetes mellitus.